Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Excellent quarterly results but unexplainable drop in sp this morning!
...For the three months to March 31, Indivior reported net revenue of USD284 million, up 12% from USD253 million a year prior.
Net income rose 7% to USD47 million from USD44 million, while pretax profit rose 8.6% to USD63 million from USD58 million.
Jefferies raises Indivior price target to 2,390 (2,165) pence - 'buy' (12 March 2024)
More good news!
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
OPVEE shows rapid reversal of opioid effects in study
OPVEE shows rapid reversal of opioid effects in study
Investing.com | Editor Brando Bricchi
Published Mar 11, 2024 18:52
Be the first to comment
OPVEE shows rapid reversal of opioid effects in study
RICHMOND, Va. - Indivior PLC (LSE/Nasdaq: LON:INDV) has announced the results of a pharmacodynamic study indicating that its drug OPVEE® can quickly reverse opioid-induced respiratory depression, a major cause of death in opioid overdoses. The study, comparing intranasal nalmefene (OPVEE) with intranasal naloxone, was published in the Journal of Clinical Pharmacology.
The study met its primary endpoint by showing that OPVEE reversed respiratory depression within five minutes of administration, while naloxone took 20 minutes to achieve a similar effect. Minute ventilation, a measure of breathing, reached approximately 95% of the pre-opioid baseline within five minutes after OPVEE was administered.
In the study, 69 healthy volunteers experienced a reduction in minute ventilation after being administered remifentanil, a synthetic opioid. They were then treated with either OPVEE or naloxone. OPVEE was found to be non-inferior and superior to naloxone in the speed of reversing opioid-induced respiratory depression.
ADVERTISEMENT
Although adverse events were reported in over 90% of subjects following both drugs, these were mostly mild to moderate and were attributed to the remifentanil and experimental conditions rather than the drugs themselves. Common adverse events included headache, nausea, vomiting, and dizziness.
Get The App
Join the millions of people who stay on top of global financial markets with Investing.com.
Download Now
The urgency for rapid-acting opioid reversal agents is underscored by the high number of opioid overdose deaths, which in the United States totaled over 80,000 in the 12 months ending in September 2023, with synthetic opioid
Article from Investing.com (Published Mar 11, 2024 18:52)
https://uk.investing.com/news/stock-market-news/opvee-shows-rapid-reversal-of-opioid-effects-in-study-93CH-3376280
I will take my prediction back from yesterday as £18 quite possibe today with thus game changing news
A bit of profit taking by the Directors, nothing to worry about and certainly no concerning news otherwise it would be tantamount to insider trading which is of course illegal. Of course it's not ideal when Directors sell but they've only top sliced and still have significant holdings so onwards and upwards from here. My target is still £18 in the short term, and hoping it hits that by March end.
LAST RNS 22 February 2024: Following the above transaction and cancellation of the purchased shares, Indivior has 135,272,708 ordinary shares with voting rights in issue.
Today's RNS : Following the above transaction and cancellation of the purchased shares, Indivior has 136,490,175 ordinary shares with voting rights in issue.
How on earth has the outstanding company shares total jumped up by 1.22 million shares?
One to send to I.R. because it is not correct.
Is the company share buy back declared on 17 November 2023 complete? There has been no RNS for the last 2 business days in respect to the same.
Indivior Announces Q4 / FY 2023 Financial Results – Company Announcement
Bumper results and exceptional growth, should see a nice sp rally now.
Indivior PLC announces an Equity Buyback for 13,631,504 shares, for $100 million. Indivior PLC (LSE:INDV) announces a share repurchase program. Under the program, the company will repurchase up to 13,631,504 shares for $100 million worth of shares. The purpose of the program is to reduce share capital of the company. (17 Nov 2023).
Share price has just taken off to 1431p with a massive 334k buy at 13:33hrs. Nice jump!
No doubt loading up before results in 10 days - 22 February 2024.
Could see 1600p+ post results.
Indivior has issues but it’s still too cheap, says BlackRock Throgmorton
BlackRock manager Dan Whitestone believes Indivior (INDV) shares are too cheap despite legal and competition concerns.
Whitestone holds the pharmaceutical group, which specialises in opioid addiction treatments, in his £584m BlackRock Throgmorton (THRG) closed-ended investment trust.
The shares in the group have been weak recently following the slightly higher cost of settling the bulk of its outstanding legal issues.
‘With continued strong trading in the core and regulatory risk in the rear-view mirror, we are frustrated by the performance of the shares which have been impacted by a few factors in recent months,’ said Whitestone.
This includes ‘a poorly-explained acquisition’ that saw it insource some manufacturing, ‘some higher-than expected selling general, and administrative costs’, and the launch of a competitor product and some weaker prescription data.
‘The first two we are less concerned about and think represents management sensibly investing some of the earnings beats into strengthening the business,’ said Whitestone.
‘We are keeping a closer eye on the prescription data and the competitor and have discussed both at length with management.’
The shares, which were at £13.74 on Monday, are ‘too cheap’, the manager added, pointing out they are trading at under 10x price/earnings and a double-digit percentage of its market cap is in net cash.
(P.S. Holding this time for £18.00. Not bothered if it takes 6-12 months . I admit I sold at the wrong time previously. Yes frustrating!).
Brent could well hit $90 tomorrow and reverse last weeks drop on the old fake news recession looming (we've heard that BS from the States for over 18 months,,,, wake up people!)
Wow! Brent has just shot up $4 already, now at $88. Bodes very well for Oiliers to profit during the M/E turmoil, hopefully transpires into a good week for Tullow sp.
BigRisky - that's a big positive. Let's hope a sp rise transpires today.
JPMorgan reinitiates Tullow Oil with 'overweight' - price target 55 pence.
With Brent Oil price at $95.5 per barrel Tullow sp below 45p is absolutely Criminal!
I appreciate the Oil majors stand to benefit the most and are nearing year highs i.e. BP and Shell.
However, the small caps such as Tullow will still generate plenty of FCF and therefore the MMs need to stop rap!ng this beatch.
Oil has risen 30% and this beatch is still stuck at 35p.
Agreed Scooby.
Hopefully if oil price holds up and half decent results on Wednesday we should be north of 40p here.
Re. Supercooper
Tullows H1 results is an entirely different proposition. Enq and Hbr both got hammered due to the special windfall tax on North Sea oiliers at effectively 75%.
For smaller players such as Harbour Energy and Enquest the windfall tax was a more serious proposition as almost all of their profits would be taxed at the higher rate of 75%, since 90% of production takes place at five key hubs in the UK.
In 2022/23, the UK government's North Sea revenue was 10.57 billion British pounds, compared with 2.66 billion in the previous reporting year.
Sp rather subdued despite Brent oil price at the highest since Nov 2022. Last time it was at this level tullow sp was circa. 48p.
We've had no profit warnings so if anything results will be as expected or slightly better on Wednesday.
Great time to buy in.
GLA
The last time Brent Oil was $90 the Tullow sp was circa. 48p so we are still 9p off or thereabouts. Plenty of upside here and with the added production cuts announced earlier today we should see oil price stabilise and stay in the 90s at least. Tomorrow let's break the 40p barrier.
GLA LTH.
Btw Welcome back Anton.
Frasers Group building a circa 10% stake no brainer to get into Boo now. No reason why it can't get back to 50s over the next few weeks.
All the negative news is built into the price sub 50p.
Assets alone would value Boo at circa 65p not including I.P. etc.
Half decent results on 3 October for H1-23 would push this into 60s.
I'm planning on holding until the end of year and see if I can get close to double my investment.